Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease
Critical to development of new therapies for Alzheimer’s disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable and somewhat insensitive to change in this slow...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Behavioural Neurology |
| Online Access: | http://dx.doi.org/10.3233/BEN-2009-0241 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524819307266048 |
|---|---|
| author | Adam S. Fleisher Michael Donohue Kewei Chen James B. Brewer Paul S. Aisen the Alzheimer’s Disease Neuroimaging Initiative |
| author_facet | Adam S. Fleisher Michael Donohue Kewei Chen James B. Brewer Paul S. Aisen the Alzheimer’s Disease Neuroimaging Initiative |
| author_sort | Adam S. Fleisher |
| collection | DOAJ |
| description | Critical to development of new therapies for Alzheimer’s disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable and somewhat insensitive to change in this slowly progressive disease. For this reason, development of surrogate biomarkers that identify significant disease-associated brain changes are necessary to expedite treatment development in AD. Since AD pathology is present in the brain many years prior to clinical manifestation, ideally we want to develop biomarkers of disease that identify abnormal brain structure or function even prior to cognitive decline. Magnetic resonance imaging, fluorodeoxyglucose positron emission tomography, new amyloid imaging techniques, and spinal fluid markers of AD all have great potential to provide surrogate endpoint measures for AD pathology. The Alzheimer’s disease neuroimaging initiative (ADNI) was developed for the distinct purpose of evaluating surrogate biomarkers for drug development in AD. Recent evidence from ADNI demonstrates that imaging may provide more sensitive, and earlier, measures of disease progression than traditional clinical measures for powering clinical drug trials in Alzheimer's disease. This review discusses recently presented data from the ADNI dataset, and the importance of imaging in the future of drug development in AD. |
| format | Article |
| id | doaj-art-07e24ef99f5a4ce085557a19caa9060f |
| institution | Kabale University |
| issn | 0953-4180 1875-8584 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Behavioural Neurology |
| spelling | doaj-art-07e24ef99f5a4ce085557a19caa9060f2025-02-03T05:47:19ZengWileyBehavioural Neurology0953-41801875-85842009-01-01211-212913610.3233/BEN-2009-0241Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s DiseaseAdam S. Fleisher0Michael Donohue1Kewei Chen2James B. Brewer3Paul S. Aisen4the Alzheimer’s Disease Neuroimaging InitiativeDepartment of Neurosciences, University of California, San Diego, USADivision of Biostatistics and Bioinformatics, University of California, San Diego, USABanner Alzheimer's Institute, Phoenix, AZ, USADepartment of Neurosciences, University of California, San Diego, USADepartment of Neurosciences, University of California, San Diego, USACritical to development of new therapies for Alzheimer’s disease (AD) is the ability to detect clinical or pathological change over time. Clinical outcome measures typically used in therapeutic trials have unfortunately proven to be relatively variable and somewhat insensitive to change in this slowly progressive disease. For this reason, development of surrogate biomarkers that identify significant disease-associated brain changes are necessary to expedite treatment development in AD. Since AD pathology is present in the brain many years prior to clinical manifestation, ideally we want to develop biomarkers of disease that identify abnormal brain structure or function even prior to cognitive decline. Magnetic resonance imaging, fluorodeoxyglucose positron emission tomography, new amyloid imaging techniques, and spinal fluid markers of AD all have great potential to provide surrogate endpoint measures for AD pathology. The Alzheimer’s disease neuroimaging initiative (ADNI) was developed for the distinct purpose of evaluating surrogate biomarkers for drug development in AD. Recent evidence from ADNI demonstrates that imaging may provide more sensitive, and earlier, measures of disease progression than traditional clinical measures for powering clinical drug trials in Alzheimer's disease. This review discusses recently presented data from the ADNI dataset, and the importance of imaging in the future of drug development in AD.http://dx.doi.org/10.3233/BEN-2009-0241 |
| spellingShingle | Adam S. Fleisher Michael Donohue Kewei Chen James B. Brewer Paul S. Aisen the Alzheimer’s Disease Neuroimaging Initiative Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease Behavioural Neurology |
| title | Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease |
| title_full | Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease |
| title_fullStr | Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease |
| title_full_unstemmed | Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease |
| title_short | Applications of Neuroimaging to Disease-Modification Trials in Alzheimer’s Disease |
| title_sort | applications of neuroimaging to disease modification trials in alzheimer s disease |
| url | http://dx.doi.org/10.3233/BEN-2009-0241 |
| work_keys_str_mv | AT adamsfleisher applicationsofneuroimagingtodiseasemodificationtrialsinalzheimersdisease AT michaeldonohue applicationsofneuroimagingtodiseasemodificationtrialsinalzheimersdisease AT keweichen applicationsofneuroimagingtodiseasemodificationtrialsinalzheimersdisease AT jamesbbrewer applicationsofneuroimagingtodiseasemodificationtrialsinalzheimersdisease AT paulsaisen applicationsofneuroimagingtodiseasemodificationtrialsinalzheimersdisease AT thealzheimersdiseaseneuroimaginginitiative applicationsofneuroimagingtodiseasemodificationtrialsinalzheimersdisease |